<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-09000536</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2009-09-28</date_registration>
      <primary_sponsor>Sun Yat-sen University</primary_sponsor>
      <public_title>A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease</public_title>
      <acronym />
      <scientific_title>Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2009-09-01</date_enrolment>
      <type_enrolment />
      <target_size>A:26;B:26;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=8999</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Extensive chronic graft versus host disease</hc_freetext>
      <i_freetext>A:Glucocorticoids+CSA/FK506;B:Glucocorticoids+CSA/FK506+MSC;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Wei Ling</firstname>
        <middlename />
        <lastname />
        <address>No.106, Second Zhongshan Road, Guangzhou, China</address>
        <city />
        <country1 />
        <zip>510080</zip>
        <telephone>+86 020 83889772</telephone>
        <email>lingwei97@163.com</email>
        <affiliation>Department of Hemotology, Guangdong General Hospital, Guangdong Academy of Medical  Sciences</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xin Du</firstname>
        <middlename />
        <lastname />
        <address>No.106, Second Zhongshan Road, Guangzhou, China</address>
        <city />
        <country1 />
        <zip>510080</zip>
        <telephone>+86 020 83827812-62122</telephone>
        <email>miyadu@hotmail.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Informed consent obtained from patient and donor;
2. Any patient who has undergone allogeneic stem cell transplantation with extensive chronic GVHD;
3. Have not received additional agent for cGVHD within 3 months;
4. Expected life is more than 90 days;
5. Adequate pulmonary function with no evidence of chronic obstructive or severe restrictive pulmonary disease;
6. Adequate cardiac function with no evidence of uncontrolled high blood pressure,congestive heart failure, angina pectoris, acute myocardial infarction within 6 months prior to the process.</inclusion_criteria>
      <agemin>0</agemin>
      <agemax>0</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Invasive fungal disease; 
2. Active cytomegalovirus (CMV)/Epstein-Barr virus(EBV)/varicella disease); 
3. Patient is with a history of hypersensitivity to bovine products;
4. Relapsed malignancy.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Remission rate (CR and PR);Safety of MSC treatment;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Effect on OS, DFS and QOL;The total Response rate;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-finance</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-08-01</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>